Señor editor: El cáncer de mama es la neoplasia más frecuente entre las mujeres, con un estimado de 1.67 millones de nuevos casos diagnosticados en 2012 (25% de todos los cánceres). Entre 1990 y 2013, las tasas de incidencia estandarizada por edad por cada 100 000 mujeres han incrementado en 17% a nivel mundial, siendo más afectados los países en desarrollo, donde cerca de la mitad de los casos corresponden a una enfermedad avanzada debido al diagnóstico tardío y al pobre acceso al tratamiento. En Perú, el cáncer de mama ocupa la segunda causa de muerte por cáncer en mujeres, detrás del cervicouterino, y su supervivencia se estima en alrededor de 60 a 70% a los cinco años del diagnóstico...

[No abstract available]

[Not available]

Background: Previous studies have reported a higher prevalence of triple-negative breast cancer (TNBC) in US Hispanic/Latina populations. However, survival outcomes and treatment approaches over time in Latin American females are scarcely reported. We aimed to evaluate the temporal variation in treatment patterns and overall survival (OS) outcomes of females with TNBC according to cancer stage. Materials and Methods: We performed a single-center retrospective cohort study on 1840 females from 2000 to 2014. Patients were classified in 3 calendar periods (2000-2004, 2005-2009, and 2010-2014). The Kaplan-Meier method and multivariable regression analyses were employed. Results: Stage III cancer was identified in half of the population. Five-year OS estimates for cancer stages I, II, and IV remained unchanged across all calendar periods. However, we found worsening 5-year OS estimates in sta...

Background: The aim of this study was to determine the utility of the neutrophil-to-lymphocyte ratio (NLR) as a biomarker for predicting early-mortality (<2 years) among females with metastatic triple-negative breast cancer (mTNBC). Methods: We reviewed 118 medical records of females with mTNBC. The cut-off value for the NLR (<2.5 and ≥2.5) was determined with receiver operating characteristic curves (area under the curve: 0.73; 95% CI: 0.62-0.85). Survival curves were estimated using the Kaplan-Meier method and compared with the Log-rank test. Multivariate Cox regression was used to identify the risk of mortality at two years. Moreover, we performed sensitivity analyses with different cut-off values and a subgroup analysis in females that only received chemotherapy. Results: The median follow-up was 24 months. Females with NLR ≥2.5 had a poor overall survival compared to females wit...